Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Conditions
Brief summary
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
Interventions
DRUGXL092
oral doses of XL092
DRUGAtezolizumab
Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
DRUGAvelumab
Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
Sponsors
Exelixis
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
single-agent and combination therapy dose-escalation followed by cohort-expansion
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent. * Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. * Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component) who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease. * Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with non-clear cell histology who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease. * Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor receptor 2 (HER-2) and who have radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease. * Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology. * Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type (confirmed via local testing report) and determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC: * Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF monoclonal antibody (bevacizumab) * Anti-EGFR monoclonal antibody (cetuximab or panitumumab) * BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations * Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1. * Tumor tissue material: * Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained. * Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. * Adequate organ and marrow function. * Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception. * Female subjects of childbearing potential must not be pregnant at screening.
Exclusion criteria
* Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only), or prior treatment with regorafenib and/or TAS-102 (Cohort H only). * Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment. * Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal anticancer therapy within 4 weeks before first dose of study treatment. * Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. * Uncontrolled, significant intercurrent or recent illness. * Concomitant use of certain medications. * Corrected QT interval calculated by the Fridericia formula (QTcF) \> 450 ms for males and \> 470 ms for females. Single ECGs are no longer permitted. * Pregnant or lactating females. * Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-Escalation Stage: MTD/recommended dose for XL092 | Up to 24 months | To determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with immune checkpoint inhibitors (ICIs) to subjects with advanced solid tumors |
| Cohort-Expansion Stage: Objective Response Rate (ORR) | Up to 24 months | To evaluate preliminary efficacy of XL092 when administered alone and in combination with ICIs by estimating ORR as assessed by the Investigator per RECIST 1.1 |
| Cohort-Expansion Stage (except Cohort H): Progression-Free Survival (PFS) | Up to 24 months | To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with ICIs for specific cohorts by estimating the percentage of subjects with PFS at 6 months (PFS rate) per RECIST 1.1 as assessed by the Investigator (except for the CRC expansion cohort H) |
| Cohort-Expansion Stage (Cohort H only): Overall Survival (OS) | Up to 24 months | To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with atezolizumab for subjects with RAS wild-type CRC (Cohort H Treatment Arms H-A and H-B) by estimating overall survival (OS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dose-Escalation Stage: Terminal Half-Life | Up to 24 months | To evaluate the terminal half-life of XL092 alone and in combination with ICI |
| Incidence and Severity of Nonserious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 36 months | To evaluate the safety of XL092 when administered alone and in combination with ICIs through the evaluation of incidence and severity of nonserious AEs and SAEs, including immune-related adverse events (irAEs), and adverse events of special interest (AESIs) |
| Dose-Escalation Stage: Apparent Clearance (CL/F) | Up to 24 months | To evaluate the CL/F of XL092 alone and in combination with ICI |
| Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax) | Up to 24 months | To evaluate the Tmax of XL092 alone and in combination with ICI |
| Dose-Escalation Stage: Maximum Plasma Concentration (Cmax) | Up to 24 months | To evaluate the Cmax of XL092 alone and in combination with ICI |
| Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24) | Up to 24 months | To evaluate the AUC 0-24 of XL092 alone and in combination with ICI |
Countries
Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Outcome results
None listed